Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards® Scientists

Business Wire January 30, 2013

Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013

Marketwired January 28, 2013

Key to Success, How to Profit: BTX, INTC and CPLP

Marketwired January 23, 2013

BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference

Business Wire January 18, 2013

The Real Story Behind TCX, BTX, NSU and TA

Marketwired January 16, 2013

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia(tm) in Europe

Business Wire January 10, 2013

LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02

Business Wire January 9, 2013

Perfect Trade Setups, How to Play BSX, NBY, BTX and PFE

Marketwired January 9, 2013

BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets

Business Wire January 7, 2013

BioTime Announces the Appointment of Jeffrey Janus as Vice President

Business Wire December 20, 2012